Polysaccharide antigens prepared from meningococci of serogroups A and C have been shown to be immunogenic in human volunteers, both adults and young children (3, 5, 12, 13, 15, 16) . Several field tests have shown the group C polysaccharide vaccines to be effective in preventing group C meningococcal disease in U.S. Army recruits (6, 10) . Previous studies from this laboratory have shown that several lots of group A and C meningococcal polysaccharide vaccines have been equally immunogenic when the assay for antibody response was the passive hemagglutination test (1) . These same lots of vaccine have been shown to withstand storage up to one year at 4 C (1).
Among the problems which remain to be resolved if these vaccines are to achieve widespread use are: (i) the development of physical and chemical specifications for potent immunogenic vaccines, because there is no satisfactory animal model, and (ii) information concerning long-term storage of these vaccines.
In this report we present data derived from the use of Sepharose 4B chromatography for the molecular sizing (Sepharose-Agarose gels in bead form, Pharmacia Fine Chemicals, Inc.) of the polysaccharide vaccines and the radioactive antigen binding assay (8) for determining antibody response to evaluate vaccine potency.
MATERIALS AND METHODS
Vaccines. The group A and C vaccines were prepared by basic methodology described by Gotschlich et al. (14) and Berman et al. (7) . Lots A-7, A-8, C-7, C-8, and C-9 were prepared by the Squibb Institute for Medical Research (under contract with the U.S.A. Medical Research and Development Command); lots 439-A, 440-A, 419-C, 420-C, 421-C, 422-C, 423-C, 424-C, 426-C, 438-C, 487-C, 488-C, 489-C, 490-C, 491-C, 512-C, and 513-C were prepared by Merck Sharpe & Dohme Research Laboratories (under the same contract as for Squibb). Lots 1227-A and 1228-C were prepared by Merrell-National Laboratories and were kindly provided by James Sorrentino. All group A vaccines were prepared from a single strain, A-1; group C vaccines were derived from cultures of strain C-11 (14) .
Subjects, vaccinations, and collection of specimens. Army recruits in the first week of basic training received either group A or group C vaccine subcutaneously in a dose of 50 Ag. Vaccine lots were administered in sequence rather than by random selection. The number of subjects in any vaccine group varied from 18 to 50, depending upon the total number of recruits in the company unit that day. In accordance with Army regulations informed consent was obtained from all volunteers who received group A polysaccharide vaccines and from those who received group C vaccines prior to its designation as a mandatory procedure. Serum specimens were obtained prior to and 2 weeks after vaccination, except where specifically stated, and were stored at -20 C prior to and between testing. Pharyngeal cultures were obtained prior to vaccination and at the time of each postvaccination venipuncture. Isolates were characterized by techniques described previously (11) . The very few individuals shown to be nasopharyngeal carriers of group C meningococci were deleted from the calculations of the group C antibody response. No carriers of group A meningococci were found during these studies. Because only three or four lots of vaccine were tested at any one time, a control group which received a previously tested lot of vaccine was included in each study. Molecular sizing of vaccines. Molecular size of vaccine preparations was determined by gel filtration. Chromatography was accomplished by using a 2.5 x 36 cm column of Sepharose 4B (Pharmacia Fine Chemicals, Inc., Piscataway, N.J.) equilibrated with 0.05 M tris(hydroxymethyl)aminomethane-hydrochloride buffer, pH 7.4 . Flow through the column was in the ascending direction, and the flow rate was maintained at 12.5 ml/hour by using a polystaltic pump (Buchler Instruments, Fort Lee, N.J.). Samples (2 mg of group C polysaccharide or 8 mg of group A polysaccharide) were applied by using a sample injection valve loop (Chromatronic, Inc., Berkeley, Calif.). Fractions of 2.5 ml were collected in a Fractomette 200 fraction collector (Buchler Instruments, Fort Lee, N.J.). The void volume of the column was determined with blue dextran (Pharmacia Fine Chemicals, Inc., Piscataway, N.J.), and the total volume was determined with "4C-labeled sodium acetate; dextran T-500, T-250, T-150, and T-70 were used for calibration. The average distribution coefficient (K.0) was calculated from the peak elution volume of the polysaccharide (Sepharose-Agarose gels in bead form, Pharmacia Fine Chemicals, Inc.). The column was monitored for carbohydrate content in the dextran fractions by the anthrone method (17) , phosphorus by the method of Chen et al. (9) for the group A vaccines, or sialic acid in the group C vaccines by the method of Svennerholm (19) .
Serological studies. The serum specimens collected were tested for antibodies by either the indirect hemagglutination (IHA) test or by both the IHA and the radioactive antigen binding assays (RABA).
The IHA test used polysaccharide-coated human erythrocytes and was performed as previously described (4). The RABA was a modification of the method described by Brandt et al. (8) 8, 1973 two-week postimmunization antibody titers in a group of 24 young adult volunteers who received a single subcutaneous injection of 50 ug of lot C-7 group C polysaccharide. Both the IHA and RABA assays showed the phenomenon. Similar patterns have been observed with all group C and A vaccines tested.
Comparison of IHA and RABA. A positive relationship between the RABA and IHA has been noted. By using approximately 70 pairs INFECT. IMMUNITY of sera (pre-and postvaccination) for each serogroup, a positive correlation coefficient of 0.928 (P < 0.001) has been calculated for the group C tests and 0.766 (P < 0.001) for the group A tests (Fig. 2) .
Antibody response to group A and C vaccines as measured by IHA. Over the past 4 Fig. 3 . RABA GMTs at varying intervals after a 50-Mg dose of lot A-7 showed no signif'icant changes during the first 2 years of storage at 4 C. Peak response occurred at about two weeks and fell slightlv after 7 weeks. The GMT increase of' men vaccinated in 1972 was signif'icantly lower than the response observed in 1969 (P < 0.005). Lot A-8 did not appear to deteriorate in the 1st year of storage (although strict comparisons cannot be made because sera were obtained at 11 days postvacc inat ion in 1971 rather than at 14 days). However, the 14-day response was signif'icantlv lower after 2 years of' storage (P < 0.005). When analyzed on the basis of' f'old increases in titer (Fig. 4) 
